Your browser doesn't support javascript.
loading
Next-generation sequencing reveals genetic heterogeneity and resistance mechanisms in patients with EGFR-mutated non-small cell lung cancer treated with afatinib.
Liang, Sheng-Kai; Wei, Pin-Fei; Hsieh, Min-Shu; Wu, Chia-Ling; Shih, Jin-Yuan.
Afiliación
  • Liang SK; Department of Medicine, National Taiwan University Cancer Center, Taipei, Taiwan.
  • Wei PF; Department of Internal Medicine, National Taiwan University Hospital Hsinchu Branch, Hsinchu, Taiwan.
  • Hsieh MS; Graduate Institute of Medical Genomics and Proteomics, College of Medicine, National Taiwan University, Taipei, Taiwan.
  • Wu CL; Department of Laboratory Medicine, National Taiwan University Hospital, Taipei, Taiwan.
  • Shih JY; Department of Pathology, National Taiwan University Hospital, Taipei, Taiwan.
ERJ Open Res ; 10(2)2024 Mar.
Article en En | MEDLINE | ID: mdl-38500795
ABSTRACT

Background:

Afatinib, an irreversible ErbB family inhibitor, is widely used as first-line treatment in advanced lung adenocarcinoma patients harbouring mutant epidermal growth factor receptor (EGFR). With the advancements in next-generation sequencing (NGS), comprehensive research into the clinical impact of co-occurring genetic mutations and the molecular mechanisms of acquired resistance is required for afatinib users. Materials From January 2010 to December 2019, we enrolled patients with advanced lung adenocarcinoma with EGFR mutations using afatinib as first-line treatment, and we retrospectively collected pre- and post-afatinib treatment specimens from these patients for NGS testing.

Results:

Of the 362 enrolled patients, 73 samples (68.9%) from 56 patients successfully returned complete NGS reports. In pre-afatinib treatment specimens, the most frequent co-occurring alterations were TP53, MUC16, USH2A, SNYE1, RECQL4 and FAT1; however, they were not related to progression-free survival. Small cell lung cancer transformation, EGFR p.T790M, amplification of MET, ERBB2, KRAS, EGFR, cell cycle-regulated genes and MDM2, and PTEN alterations were identified as acquired resistance mechanisms. EGFR p.T790M (p=0.0304) and APC alterations (p=0.0311) in post-afatinib specimens were significantly associated with longer overall survival, while MET amplification was significantly associated with poor overall survival (p=0.0324). The co-occurrence of TP53 alterations was significantly associated with shorter overall survival (p=0.0298).

Conclusions:

Our results show that the frequent co-occurring alterations in advanced EGFR-mutated lung adenocarcinoma did not influence the effectiveness of afatinib. EGFR p.T790M is not only the major resistance mechanism to afatinib but also related to favourable survival outcomes. MET amplification and TP53 mutations were associated with poorer overall survival.

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: ERJ Open Res Año: 2024 Tipo del documento: Article País de afiliación: Taiwán

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: ERJ Open Res Año: 2024 Tipo del documento: Article País de afiliación: Taiwán
...